Aug 1, 2019
MediSieve CEO Winner of BBSRC Innovator of the Year Award
Dr George Frodsham has won the Early Career Impact Award at the BBSRC Innovator of the Year Awards 2019.
LONDON – August 01, 2019 – The award was presented by Chris Skidmore MP, Minister of State for Universities, Science, Research and Innovation at a glamorous awards ceremony in the Science Museum, London.
Dr George Frodsham, founder and CEO at MediSieve, the medical device company developing ‘magnetic blood filtration’, has won the Early Career Impact Award at the BBSRC Innovator of the Year Awards 2019. The award was presented by Chris Skidmore MP, Minister of State for Universities, Science, Research and Innovation at a glamorous awards ceremony in the Science Museum, London.
This comes just a short time after MediSieve won the highly competitive award category of Investment Achievement at the MedTech London Awards 2019.
“I am thrilled to receive this prestigious award from the BBSRC, underlining the great progress that we have made at MediSieve since spinning out four years ago. It’s truly flattering to be recognised by one of the UK’s biggest research councils and to have the opportunity to stand alongside winners of the award in other categories, who are all so inspiring.” said Dr Frodsham.
“The Innovator of the Year awards continue to successfully recognise researchers and their teams for focussing their talents on transforming the future,” said Professor Melanie Welham, Executive Chair of BBSRC.
“I congratulate all the named winners of the Innovator of the Year competition, and I anticipate their successes will continue to push the boundaries of bioscience, driving innovative solutions with the potential to change the world forward.”
BBSRC is part of UK Research and Innovation. BBSRC Innovator of the Year recognises and rewards individuals and small teams who have harnessed the potential of their excellent research. It is designed to recognise the full breadth of impacts that BBSRC investments in research have, from creation of spinout companies or social enterprises, to working in collaboration with business and NGOs, to working with policy makers, both in the UK and abroad.
Earlier this year, MediSieve announced that it had received two grants from Innovate UK, worth around £1.56m; one large biomedical catalyst grant will progress development of a severe sepsis product, developing five magnetic particles to remove different sepsis targets. The second Scientific Research-Based Interventions (SRBI) grant, enables further focus on one of those particles and how it can be used to remove anti-microbial resistant (AMR) bacteria from a patient’s bloodstream.
“These grants are of huge benefit to us and to patients suffering from sepsis. MediSieve will be able to accelerate its development and validation of more products to address the medical challenges posed by sepsis,” said Frodsham.
“Winning these awards is a huge boost for the MediSieve team and reflects the amazing work the team carries out around the development of magnetic blood filtration products to successfully treat blood-borne diseases,” said Frodsham.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
